$1.43 -0.06 (-4.03%)
2/10/2012 4:00 PM

Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Featured Broker Partners


Advertisement